|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Pediatric Neuro-Oncology |
University of Wisconsin, Madison, WI 53706 (S.N.S., M.P.M.); ImClone Systems Inc., Somerville, NJ 08876 (M.N.N.); Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 (M.D.K.); Children's Hospital and Regional Medical Center, Seattle, WA 98105 (J.R.G.); and M. D. Anderson Cancer Center, Houston, TX 77030 (J.A.)
2 Address correspondence and reprint requests to Minesh P. Mehta, M.D., Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue, K4/3, Madison, WI 53792.
Abstract
Our purpose was to establish the maximum tolerated dosage (MTD) of daily i.v. topotecan with conventionally fractionated radiotherapy (XRT) for patients with intrinsic pontine glioma of childhood. Topotecan was given as a 30-min i.v. infusion 30-60 min before each XRT treatment given daily for 33 days. Total XRT dose was 59.4 Gy. Dose escalation of topotecan was carried out using a standard phase I design. Dose limiting toxicity (DLT) was defined as an absolute neutrophil count (ANC) of <500/mm3 for >7 days; platelets of <50,000/mm3 for >7 days; >7 days platelet transfusions; fever and neutropenia (ANC <500/mm3 for >7 days); and/or any > grade 3 nonhematologic toxicity. In this multi-institutional phase I study, 17 patients <21 years with intrinsic pontine glioma were enrolled. Sixteen patients completed treatment. An ANC <500/mm3 for >7 days occurred in 2/5 patients at 0.50 mg/m2 of topotecan, which was the DLT. The remaining 14 patients received topotecan without experiencing DLT. One patient at 0.40 mg/m2 died of disease progression while on treatment. There were 6 other grade 4 hematologic events (5 ANCs <500/mm3, 1 hemoglobin <6. 5 g/dl) not meeting DLT criteria. No significant nonhematologic toxicities were seen. The actuarial median survival time is 15 months (95% confidence interval, 9.6-19 months); 1-year survival is 53%. DLT of daily topotecan with cranial XRT is grade 4 neutropenia for >7 days at 0.50 mg/m2 x 33 (total dosage = 16.5 mg/m2); the recommended safe MTD of daily topotecan for further phase II testing is 0.40 mg/m2 x 33 (total dosage = 13.2 mg/m2).
References
Albright, A.L., Guthkelch, A.N., Packer, R.J., Price, R.A., and Rourke, L.B. (1986) Prognostic factors in pediatric brain-stem gliomas. J. Neurosurg. 65,751 -755.[ISI][Medline]
Allen, J.C., and Siffert, J. (1996) Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr. Neurosurg. 24,98 -102.[Medline]
Berger, M.S., Edwards, M.S., LaMasters, D., Davis, R.L., and Wilson. C.B. (1983) Pediatric brain stem tumors: Radiographic, pathological, and clinical correlations. Neurosurgery 12,298 -302.[Medline]
Boothman, D.A., Trask, D.K., and Pardee, A.B. (1989)
Inhibition of potentially lethal DNA damage repair in human tumor cells by
B-lapachone, an activator of topoisomerase I. Cancer
Res. 49,605
-612.
Boothman, D.A., Wang, M., Schea, R.A., Burrows, H.L., Strickfaden, S., and Owens, J.K. (1992) Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24,939 -948.[Medline]
Chabner, B.A. (1992) Camptothecins. J. Clin. Oncol. 10,3 -4.
Epstein, F., and Constantini, S. (1996) Practical decisions in the treatment of pediatric brain stem tumors. Pediatr. Neurosurg. 24,24 -34.[Medline]
Fischbein, N.J., Prados M.D., Wara, W., Russo, C., Edwards, M.S., and Barkovich, A.J. (1996) Radiologic classification of brain stem tumors: Correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr. Neurosurg. 24, 9-23.[ISI][Medline]
Freeman, C.R., Krischer, J.P., Sanford, R.A., Cohen, M.E., Burger, P.C., del Carpio, R., Halperin, E.C., Munoz, L., Friedman, H.S., and Kun, L.E. (1993) Final results of a study of escalating doses of hyperfractionated radiotherapy in brainstem tumors in children: A Pediatric Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 27,197 -206.[ISI][Medline]
Greenberger, J.S., Cassady, J.R., and Levene, M.B. (1977) Radiation therapy of thalamic, midbrain, and brain stem gliomas. Radiology 122,463 -468.[Abstract]
Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., and Vinci, R.Z. (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J. Clin. Oncol. 12,553 -559.[Abstract]
Jenkin, R.D., Boesel, C., Ertel, I., Evans, A., Hittle, R., Ortega, J., Sposto, R., Wara, W., Wilson, C., and Anderson, J. (1987) Brain-stem tumors in childhood: A prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study. J. Neurosurg. 66,227 -233.[Medline]
Kalbfleisch, J.D., and Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons.
Kim, J.H., Kim, S.H., Kolozsvary, A., and Khil, M.S. (1992) Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22,515 -518.[Medline]
Lamond, J.P., Mehta, M.P., and Boothman, D.A. (1996) The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. J. Neurooncol. 30,1 -6.[Medline]
Lamond, J.P., Wang, M., Kinsella, T.J., and Boothman, D.A. (1996) Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 36,361 -368.[Medline]
Linstadt, D.E., Edwards, M.S.B., Prados, M., Larson, D.A., and Wara W.M. (1991) Hyperfractionated irradiation for adults with brainstem gliomas. Int. J. Radiat. Oncol. Biol. Phys. 20,757 -760.[ISI][Medline]
Mandell, L.R., Kadota, R., Freeman, C., Douglass, E.C., Fontanesi, J., Cohen, M.E., Kovnar, E., Burger, P., Sanford, R.A., Kepner, J., Friedman, H., and Kun, L.E. (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results of a Pediatric Oncology Group Phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 43,959 -964.[CrossRef][ISI][Medline]
Mattern, M.R., Hofmann, G.A., McCabe, F.L., and Johnson, R.K.
(1991) Synergistic cell killing by ionizing radiation and
topoisomerase I inhibitor topotecan. Cancer Res.
51,5813
-5816.
Packer, R.J., Boyett, J.M., Zimmerman, R.A., Rorke, L.B., Kaplan, A.M., Albright, A.L., Selch, M.T., Finlay, J.L., Hammond, G.D., and Wara, W.M. (1993) Hyperfractionated radiation therapy (72Gy) for children with brain stem gliomas. Childrens Cancer Group Phase I/II Trial. Cancer 72,1414 -1421.[CrossRef][ISI][Medline]
Panitch, H.S., and Berg, B.O. (1970) Brain stem tumors of childhood and adolescence. Am. J. Dis. Child. 119,465 -472.[Medline]
Prados, M.D., Wara, W.M., Edwards, M.S., Larson, D.A., Lamborn, K., and Levin, V.A. (1995) The treatment of brainstem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 32,85 -91.[CrossRef][Medline]
Rowinsky, E.K., Grochow, L.B., Hendricks, C.B., Ettinger, D.S.,
Forastiere, A.A., Hurowitz, LA., McGuire, W.P., Sartorius, S.E., Lukejko,
B.G., and Kaufmann, S.H. (1992) Phase I and pharmacologic study
of topotecan: A novel topoisomerase inhibitor. J. Clin.
Oncol. 10,647
-656.
Schiller, J.H., Kim, K., and Johnson, D. (1994) Phase II study of topotecan in extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13, 330. (abstract)
Stroink, A.R., Hoffman, H.J., Hendrick, E.B., and Humphreys, R.P. (1986) Diagnosis and management of pediatric brain-stem gliomas. J. Neurosurg. 65,745 -750.[ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  N. Sirachainan, S. Pakakasama, A. Visudithbhan, S. Chiamchanya, L. Tuntiyatorn, M. Dhanachai, J. Laothamatas, and S. Hongeng Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma Neuro-oncol, August 1, 2008; 10(4): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Bradley, I. F. Pollack, J. M. Reid, P. C. Adamson, M. M. Ames, G. Vezina, S. Blaney, P. Ivy, T. Zhou, M. Krailo, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study Neuro-oncol, January 1, 2008; 10(5): 752 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Broniscer and A. Gajjar Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist Oncologist, April 1, 2004; 9(2): 197 - 206. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
